Mark Eisner

Mark Eisner

Company: FibroGen

Job title: Chief Medical Officer

Seminars:

Analyzing the Latest from Phase III IPF Clinical Trials 8:40 am

Understanding the likely next therapies to hit the market Accentuating the lessons learned from the trials and what to consider for the future Considering how mechanism of action may translate into efficacy Understanding the clinical trial endpoints usedRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.